IRIDEX Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRIDEX stock.
View analyst ratings for IRIDEX or view top-rated stocks.

Wall Street analysts have given IRIDEX a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IRIDEX wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

IRIDEX is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for IRIDEX.

IRIDEX Co. (NASDAQ:IRIX) posted its quarterly earnings results on Tuesday, May, 11th. The medical equipment provider reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.14). The medical equipment provider earned $11.96 million during the quarter, compared to the consensus estimate of $9.90 million. IRIDEX had a negative net margin of 5.41% and a negative trailing twelve-month return on equity of 25.31%.
View IRIDEX's earnings history.

IRIDEX's stock was trading at $1.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IRIX stock has increased by 260.4% and is now trading at $7.10.
View which stocks have been most impacted by COVID-19.

IRIDEX updated its FY 2021 earnings guidance on Thursday, September, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50 million-$52 million, compared to the consensus revenue estimate of $50.53 million.

1 Wall Street analysts have issued twelve-month target prices for IRIDEX's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate IRIDEX's stock price to reach $11.00 in the next year. This suggests a possible upside of 54.9% from the stock's current price.
View analysts' price targets for IRIDEX or view top-rated stocks among Wall Street analysts.

7 employees have rated IRIDEX CEO Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among IRIDEX's employees.

Some companies that are related to IRIDEX include Stereotaxis (STXS), Zynex (ZYXI), Edap Tms (EDAP), Second Sight Medical Products (EYES), Movano (MOVE), FONAR (FONR), Electromed (ELMD), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), ENDRA Life Sciences (NDRA), electroCore (ECOR), Yubo International Biotech (YBGJ), Fc Global Realty (FCRE), Helius Medical Technologies (HSDT) and Viveve Medical (VIVE).
View all of IRIX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Ampio Pharmaceuticals (AMPE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

IRIDEX's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.17%), Vanguard Group Inc. (3.24%), Bridgeway Capital Management LLC (1.68%), Essex Investment Management Co. LLC (1.30%), Isthmus Partners LLC (1.18%) and Dimensional Fund Advisors LP (1.16%). Company insiders that own IRIDEX stock include Robert Earle Grove and Scott Shuda.
View institutional ownership trends for IRIDEX.

IRIX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., EAM Investors LLC, Neuberger Berman Group LLC, Isthmus Partners LLC, and Invenomic Capital Management LP.
View insider buying and selling activity for IRIDEX or view top insider-selling stocks.

IRIX stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Millennium Management LLC, Bridgeway Capital Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., State Street Corp, Renaissance Technologies LLC, and PDT Partners LLC. Company insiders that have bought IRIDEX stock in the last two years include Robert Earle Grove, and Scott Shuda.
View insider buying and selling activity for IRIDEX or or view top insider-buying stocks.

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRIX stock can currently be purchased for approximately $7.10.

IRIDEX has a market capitalization of $112.41 million and generates $36.35 million in revenue each year. The medical equipment provider earns $-6,330,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

IRIDEX employs 89 workers across the globe.

The official website for IRIDEX is www.iridex.com.

IRIDEX is headquartered at 1212 Terra Bella Avenue, Mountain View CA, 94043.

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at (650) 940-4700 or via email at [email protected]